Theravance Biopharma, Inc.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2016 | $289.0M | $639.3M | $344.7M |
| FY2017 | $326.2M | $441.4M | $89.0M |
| FY2018 | $611.8M | $560.2M | $378.0M |
| FY2019 | $632.7M | $408.8M | $58.1M |
| FY2020 | $772.8M | $469.1M | $81.5M |
| FY2021 | $713.4M | $374.8M | $90.0M |
| FY2022 | $165.6M | $607.4M | $298.2M |
| FY2023 | $169.0M | $382.0M | $39.5M |
| FY2024 | $178.6M | $354.2M | $37.8M |
| FY2025 | $188.8M | $485.6M | $167.8M |